Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab in active rheumatoid arthritis previously treated with anti-TNF agents
2005-001742-16Phase 3Completed
- Sponsor
- Janssen Biotech
- Start
- Mar 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Golimumab with Placebo (2 arms). Primary endpoint: ACR20 response at Week 14. Started Mar 2006; status: completed.
02
Drugs
golimumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2005-001742-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001742-16.